Full Press Release Details
New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023.
IRD
New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
Key Takeaway: New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy